Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

71
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
71
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

53
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
53
Development of Immunocompetence01:22

Development of Immunocompetence

556
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
556
Teratogenicity01:07

Teratogenicity

3.6K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.6K
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic01:26

Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic

5.0K
Healthcare-associated infections (HAIs) occur in a healthcare facility while a person receives care for another ailment. This category also includes work-related infections among healthcare staff.
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.
5.0K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

460
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
460

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic lupus erythematosus with lupus nephritis in a child with chronic granulomatous disease: a diagnostic and therapeutic challenge.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Pegcetacoplan prophylaxis for recurrent C3 glomerulopathy with multifactorial genetic background.

Kidney international·2026
Same author

Triple Therapy With Calcineurin Inhibition Enhances Remission in Childhood-Onset Lupus Nephritis.

Kidney international reports·2026
Same author

Renal complications in pediatric sickle cell disease: results from a single-center study.

Annals of hematology·2026
Same author

Natural History and Clinical Associations with Long-Term Outcomes in Primary C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative GN.

Clinical journal of the American Society of Nephrology : CJASN·2025
Same author

Comparison of B lymphocyte profile between membranous nephropathy and idiopathic nephrotic syndrome pediatric patients.

Pediatric nephrology (Berlin, Germany)·2025

Related Experiment Video

Updated: Nov 6, 2025

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.2K

Infant botulism: an underestimated threat.

Luca Antonucci1, Cristian Locci2, Livia Schettini1

  • 1Academic Department of Pediatrics, Children's Hospital Bambino Gesù, University of Rome 'Tor Vergata', Rome, Italy.

Infectious Diseases (London, England)
|May 10, 2021
PubMed
Summary

Infant botulism (IB) is a severe neuroparalytic illness in infants caused by Clostridium botulinum. Early treatment with Human Botulism Immune Globulin Intravenous (BIG-IV) is crucial for recovery.

Keywords:
Botulism Immune GlobulinClostridium botulinumInfant botulismbotulinum neurotoxininfant

More Related Videos

Non-Invasive Model of Neuropathogenic Escherichia coli Infection in the Neonatal Rat
08:27

Non-Invasive Model of Neuropathogenic Escherichia coli Infection in the Neonatal Rat

Published on: October 29, 2014

11.3K
A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

6.6K

Related Experiment Videos

Last Updated: Nov 6, 2025

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.2K
Non-Invasive Model of Neuropathogenic Escherichia coli Infection in the Neonatal Rat
08:27

Non-Invasive Model of Neuropathogenic Escherichia coli Infection in the Neonatal Rat

Published on: October 29, 2014

11.3K
A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

6.6K

Area of Science:

  • Microbiology
  • Epidemiology
  • Pediatric Neurology

Background:

  • Infant botulism (IB) is a critical neuroparalytic disorder affecting infants under 12 months.
  • Caused by Clostridium botulinum spores, IB leads to toxin production in the infant's gut.
  • Underreporting is common due to diagnostic challenges and vague symptoms.

Purpose of the Study:

  • To synthesize current literature on IB's microbiological, epidemiological, and clinical aspects.
  • To provide a practical treatment guide for infant botulism.
  • To review advancements in IB treatment, including novel antibody therapies and vaccines.

Main Methods:

  • Narrative literature review.
  • Synthesis of microbiological data.
  • Analysis of epidemiological trends and clinical presentations.
  • Review of current and emerging treatment strategies.

Main Results:

  • IB presents with constipation, bulbar palsy, and descending paralysis, potentially causing respiratory failure.
  • Human Botulism Immune Globulin Intravenous (BIG-IV) is the standard treatment, requiring early administration.
  • New oligoclonal antibody preparations offer highly protective, animal-free therapeutic options.

Conclusions:

  • Early diagnosis and prompt treatment with BIG-IV are vital for managing infant botulism.
  • Ongoing research focuses on new antitoxins and vaccines for improved safety and efficacy.
  • A comprehensive understanding of IB is essential for effective clinical management and public health strategies.